Pfizer Using Idun Purchase As Model For Future M&A
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is using its acquisition of Idun Pharmaceuticals as a new model for how it looks at M&A: allowing acquired companies to operate independently of Pfizer's big pharma machine
You may also be interested in...
Pfizer Clarifies M&A Philosophy
Pfizer's acquisition of Idun should not be viewed as a "departure" from the company's historical approach to mergers and acquisitions, Pfizer Senior VP-Science & Technology Peter Corr said in a letter to "The Pink Sheet" DAILY
Pfizer Clarifies M&A Philosophy
Pfizer's acquisition of Idun should not be viewed as a "departure" from the company's historical approach to mergers and acquisitions, Pfizer Senior VP-Science & Technology Peter Corr said in a letter to "The Pink Sheet" DAILY
Pfizer’s Acquisition Of Idun Includes Phase II Caspase Inhibitor
Idun’s lead small molecule, IDN-6556, is thought to control apoptosis (cell death) and is in Phase II trials for liver transplantation and hepatitis C. The deal is expected to close in the second quarter.